No Data
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Signs Letter of Intent With Gen-Plus GmbH & Co KG for Potential Business Collaborations
BioNxt Signs Statement of Work With International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
BioNxt Solutions Announces ODF Cladribine Update and Financing
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
No Data